Adoptive immunotherapy for cancer.
Rosenberg
S A
SA
National Cancer Institute.
D000818:Animals; D004274:DNA, Recombinant; D004351:Drug Resistance / Q000235:genetics; D005818:Genetic Engineering; D005819:Genetic Markers; D006801:Humans; D007116:Immunization, Passive; D007167:Immunotherapy; D007376:Interleukin-2 / Q000494:pharmacology / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000628:therapy; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology / Q000637:transplantation; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000276:immunology; D008545:Melanoma / Q000628:therapy; D051379:Mice; D009355:Neomycin; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D012190:Retroviridae / Q000235:genetics; D014162:Transfection
D004274:DNA, Recombinant; D005819:Genetic Markers; D007376:Interleukin-2; D009355:Neomycin